**Supplementary Material 4.** Incidence rates of AMI, stroke, CV-related mortality, MACE, all-cause mortality, VTE, ATE, and cancer in patients with RA receiving JAKis or TNFis (Set 1).

|  |  |  |
| --- | --- | --- |
|  | RA with JAKis (n = 645) | RA with TNFis (n = 951) |
|  | 1-year follow-up | Total follow-up  | 1-year follow-up | Total follow-up  |
| **AMI** |  |  |  |  |
| Incident events, n (men/women) | 9 (1/8) | 13 (1/12) | 14 (3/11) | 30 (8/22) |
| PY | 641 | 1358 | 943 | 2419 |
| Overall incidence (n/100 PY) | 1.40  | 0.96  | 1.48  | 1.24  |
| Incidence in men (n/100 PY) | 0.63  | 0.31  | 1.15  | 1.18  |
| Incidence in women (n/100 PY) | 1.66  | 1.16  | 1.61  | 1.26  |
| **Stroke** |  |  |  |  |
| Incident events, n (men/women) | 2 (0/2) | 4 (2/2) | 11 (4/7) | 16 (5/11) |
| PY | 643 | 1370 | 944 | 2433 |
| Overall incidence (n/100 PY) | 0.31  | 0.29  | 1.17  | 0.66  |
| Incidence in men (n/100 PY) | NA | 0.62  | 1.54  | 0.73  |
| Incidence in women (n/100 PY) | 0.41  | 0.19  | 1.02  | 0.63  |
| **CV-related mortality** |  |  |  |  |
| Incident events, n (men/women) | 5 (0/5) | 8 (2/6) | 5 (1/4) | 10 (3/7) |
| PY | 642 | 1361 | 947 | 2439 |
| Overall incidence (n/100 PY) | 0.78  | 0.59  | 0.53  | 0.41  |
| Incidence in men (n/100 PY) | NA | 0.62  | 0.38  | 0.44  |
| Incidence in women (n/100 PY) | 1.03  | 0.58  | 0.58  | 0.40  |
| **MACE** |  |  |  |  |
| Incident events, n (men/women) | 14 (1/13) | 21 (4/17) | 29 (8/21) | 54 (15/39) |
| PY | 638 | 1345 | 935 | 2377 |
| Overall incidence (n/100 PY) | 2.20  | 1.56  | 3.10  | 2.27  |
| Incidence in men (n/100 PY) | 0.63  | 1.24  | 3.10  | 2.25  |
| Incidence in women (n/100 PY) | 2.71  | 1.66  | 3.10  | 2.28  |
| **All-cause mortality** |  |  |  |  |
| Incident events, n (men/women) | 5 (2/3) | 13 (4/9) | 6 (2/4) | 16 (6/10) |
| PY | 642 | 1362 | 947 | 2442 |
| Overall incidence (n/100 PY) | 0.78  | 0.96  | 0.63  | 0.66  |
| Incidence in men (n/100 PY) | 1.27  | 1.24  | 0.76  | 0.88  |
| Incidence in women (n/100 PY) | 0.62  | 0.87  | 0.58  | 0.57  |
| **VTE** |  |  |  |  |
| Incident events, n (men/women) | 0 | 2 (0/2) | 4 (1/3) | 10 (2/8) |
| PY | 645 | 1374 | 948 | 2443 |
| Overall incidence (n/100 PY) | NA | 0.15  | 0.42  | 0.41  |
| Incidence in men (n/100 PY) | NA | NA | 0.38  | 0.29  |
| Incidence in women (n/100 PY) | NA | 0.19  | 0.44  | 0.46  |
| **ATE** |  |  |  |  |
| Incident events, n (men/women) | 1 (0/1) | 1 (0/1) | 0 | 1 (0/1) |
| PY | 644 | 1373 | 950 | 2457 |
| Overall incidence (n/100 PY) | 0.16  | 0.07  | NA | 0.04  |
| Incidence in men (n/100 PY) | NA | NA | NA | NA |
| Incidence in women (n/100 PY) | 0.21  | 0.10  | NA | 0.06  |
| **Cancer (excluding non-melanoma skin cancer)** |  |  |  |  |
| Incident events, n (men/women) | 6 (1/5) | 18 (4/14) | 11 (5/6) | 21 (10/11) |
| PY | 641 | 1358 | 944 | 2421 |
| Overall incidence (n/100 PY) | 0.94  | 1.33  | 1.17  | 0.87  |
| Incidence in men (n/100 PY) | 0.64  | 1.24  | 1.92  | 1.49  |
| Incidence in women (n/100 PY) | 1.03  | 1.35  | 0.88  | 0.63  |
| **Non-melanoma skin cancer** |  |  |  |  |
| Incident events, n (men/women) | 0 | 0 | 0 | 1 (1/0) |
| PY | 645 | 1375 | 950 | 2456 |
| Overall incidence (n/100 PY) | NA | NA | NA | 0.04  |
| Incidence in men (n/100 PY) | NA | NA | NA | 0.15  |
| Incidence in women (n/100 PY) | NA | NA | NA | NA |

Rates are presented as number of events per 100 PY at risk.

RA: rheumatoid arthritis; JAKi: janus kinase inhibitor; TNFi: tumor necrosis factor inhibitor; AMI: acute myocardial infarction; CV: cardiovascular; MACE: major adverse cardiovascular event; VTE: venous thromboembolism; ATE: arterial thromboembolism; PY: person-years; NA: not applicable.